3Seifer M,Hamatake RK,Colonno RJ,et al.In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.Antimicrob Agents Chemother,1998,42(12):3200-3208.
4Ono SK,Kato N,Shiratori Y,et al.The polymerase L528M mutation cooperates with nucleotide binding-site mutations,increasing hepatitis B virus replication and drug resistance.J Clin invest,2001,107(4):449-455.
5CHANG TT.Entecavir is superior to lamivudine for treatment of HBeAg (+) chronic hepatitis B in nucleoside-naive patients.55th Annual Meeting of the American Society for the Study of Liver Diseases,Boston,2004.
6Rosmawati M.Entecavir is superior to lamivudine at reducing HBV DNA in patients with chronic hepatitis B regardless of baseline alanine aminotransferase levels.55th Annual Meeting of the American Society for the Study of Liver Diseases,Boston,2004.
7Lai CL.Entecavir (ETV) demonstrates superior histologic and virologic efficacy over lamivudine (LVD) in nucleosidenaive HBeAg (-) chronic hepatitis b:results of phase Ⅲ trial ETV-027.55th Annual Meeting of the American Society for the Study of Liver Diseases,Boston,2004.
8de Man RA,Wolters LM,Nevens F,et al.Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.Hepatology,2001,34(3):578-582.
9Levine S,Hernandez D,Yamanaka G,et al.Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.Antinicrob Agents Chemother,2002,46 (8):2525-2532.
10Sollano J.Entecavir (ETV) is superior to continued lamivudine (LVD)for the treatment of lamivudine-refractory,HBeAg(+) chronic hepatitis B:results of Phase Ⅲ Study ETV-026.55th Annual Meeting of the American Society for the Study of Liver Diseases,Boston,2004.
